TD Cowen analyst Charles Rhyee lowered the firm’s price target on CVS Health to $99 from $102 and keeps an Outperform rating on the shares. At its Investor Day, CVS management introduce 2024 guidance of at least $8.50 in adjusted EPS, adjusted operating income of at least $17.24B, and CFFO of at least $12.5B, as well as long-term adjusted EPS baseline growth of 6%, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
- Amazon exiting ‘Pay with Venmo’ button deal, says Evercore ISI
- CVS Health price target raised by $5 at Evercore ISI, here’s why
- CVS Health price target raised to $85 from $82 at Piper Sandler
- JPMorgan positive on CVS Health post investor day
- CVS CostVantage to lower value proposition offered by GoodRx, says Wells Fargo
